350 RNA-seq genomic analysis demonstrated the molecular efficacy of Risankizumab in a moderate-to-severe plaque psoriasis phase 2 clinical study

Plaque psoriasis (PsO) is a serious chronic immune dysregulation condition in which skin cells proliferate, build up, and form scales with itchy, dry raised patches. The cytokine IL-23, comprising the p19 and p40 subunits, has been implicated in the pathogenesis of psoriasis. Risankizumab, a humanized anti-IL-23 p19 antibody (single 18-mg dose at week 0, or 90- or 180-mg doses at weeks 0, 4, and 16), demonstrated superiority in the proportion of patients achieving 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) compared with ustekinumab, an anti-IL-12 p40 antibody (45 or 90 mg, according to body weight, at weeks 0, 4, and 16) in a randomized, controlled phase 2 clinical study in moderate-to-severe plaque psoriasis patients following 12 weeks of treatment.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research: Epidemiology of Skin Diseases Source Type: research